Chat GPT did a deeper analysis...
Here’s what I found about that post from Dr. Peter McCullough:
What did the X-post (formerly Twitter) claim?
The post text you referenced reads:
"RSV Shots Linked to Over 200 Safety Signals — Serious Neurological, Cardiac, and Pregnancy Harms Identified. New VAERS study finds ..."
It appears to suggest that RSV vaccines are connected to more than 200 serious adverse events (neurological, cardiac, pregnancy-related) based on a “VAERS study.”
What does reliable data actually show?
1. Background on VAERS
VAERS is a passive, voluntary reporting system that collects reports of health events following vaccination. Crucially, it does not demonstrate causation—meaning reports don’t necessarily mean the vaccine caused the event.
It's often used as an early warning tool but must be followed up with more rigorous studies to confirm any real safety concern.
2. CDC’s real-world data on RSV vaccines in older adults (May 2023–April 2024)
According to the CDC’s Morbidity and Mortality Weekly Report (MMWR):
Guillain-Barré syndrome (GBS) was reported at:
~4.4 cases per million doses of Pfizer’s Abrysvo
~1.8 cases per million doses of GSK’s Arexvy
These rates exceeded expected background levels but remain very low absolute numbers.
Other serious adverse events reported (in very small numbers):
Atrial fibrillation
Immune thrombocytopenia (ITP)
Stroke or TIA
Myocardial infarction
Encephalitis/aseptic meningitis
But again, these were extremely rare and didn’t necessarily indicate causation.
The CDC emphasized that overall, the benefits of RSV vaccination in older adults still outweigh these small observed risks. Ongoing active surveillance efforts are in place.
3. FDA labeling update on GBS
In January 2025, the FDA required updates to include Guillain-Barré syndrome (GBS) in the warning section for both Abrysvo and Arexvy vaccines. This decision was based on Medicare data showing:
Estimated 9 excess cases of GBS per million doses of Abrysvo
7 excess cases per million doses of Arexvy
Again, extremely rare in absolute terms.
4. RSV vaccine in pregnancy (Pfizer’s Abrysvo)
A study of VAERS reports in pregnant women (Aug 2023–June 2024) showed:
121 reports, with:
36% describing injection-site or systemic reactions (like headache, muscle pain)
Preterm birth noted in 31% of reports
Hypertensive disorders of pregnancy in 7%
These findings aligned with pre-licensure safety data; no new or unexpected safety signals emerged, but further monitoring continues.
Summary: How the post compares to reality
Claim from X-postReality based on CDC/FDA data“RSV Shots Linked to Over 200 Safety Signals — serious neurological, cardiac, pregnancy harms”No published study supports this. CDC/FDA data show isolated, extremely rare reports, not hundreds of confirmed signals. VAERS data are preliminary and don’t prove causation.Implies widespread harm across multiple domainsReal-world surveillance shows a very low risk of GBS (~1–9 per million doses), with other serious events being rare. CDC/FDA continue monitoring and overall assess vaccines as safe and beneficial.
Bottom Line
VAERS raw data reports can be misleading if taken at face value—they don't confirm causality, and inflated interpretations are common.
CDC and FDA analysis show only rare adverse events like GBS (still very uncommon) and align with clinical trial data.
The claim of “over 200 safety signals” is not supported by the CDC, FDA, or peer-reviewed studies.
Let me know if you'd like help reviewing safety profiles of RSV vaccines tailored to your individual needs—or help breaking down even more detailed data before discussing options with your doctor.